ranolazine

> NEW DRUG - INDEX PAGE

CLINICAL PHARMACOLOGY -
Mechanism of Action
------------------------
The mechanism of action of ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise. Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (INa). However, the relationship of this inhibition to angina symptoms is uncertain.

INDICATIONS AND USAGE
----------------
Ranexa is indicated for the treatment of chronic angina.

DOSAGE AND ADMINISTRATION
-------------------
500 mg twice daily and increase to 1000 mg twice daily, based on clinical symptoms.

DOSAGE FORMS AND STRENGTHS
------------------
Extended-release tablets: 500 mg, 1000

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.